Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from InnoCare Pharma Ltd. ( (HK:9969) ).
InnoCare Pharma Ltd. announced its audited consolidated financial results for the year ending December 31, 2024, reporting a significant increase in revenue and gross profit. The company’s total revenue rose by 36.7% to RMB1,009.4 million, driven by a 49.1% increase in sales of orelabrutinib, a key product, due to strong commercial execution and growth in MZL indications. Despite a loss for the year, the gross profit margin improved to 86.3%, attributed to a favorable sales mix and enhanced manufacturing efficiency. This financial performance highlights InnoCare’s strengthened market position and operational efficiency.
More about InnoCare Pharma Ltd.
InnoCare Pharma Ltd. is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs. The company is primarily involved in the healthcare industry, with a market focus on providing treatments for various medical conditions.
YTD Price Performance: 36.93%
Average Trading Volume: 8,505,150
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.64B
For a thorough assessment of 9969 stock, go to TipRanks’ Stock Analysis page.